Dyne Therapeutics Q1 adjusted EPS beats expectations on lower expenses

Dyne Therapeutics

11/05/2026 12:38

Overview

US biotech reported Q1 adjusted EPS beat analyst expectations

Q1 net loss slightly missed analyst expectations

R&D expenses fell due to timing of manufacturing batches; G&A rose on launch preparation

Outlook

Dyne expects to submit BLA for z-rostudirsen in DMD in Q2 2026

Company targets potential U.S. launch of z-rostudirsen in Q1 2027, pending approval

Dyne expects to complete enrollment in z-basivarsen ACHIEVE trial in Q2 2026

Result Drivers

R&D EXPENSES - Decrease in R&D expenses was primarily due to timing of manufacturing batches for z-rostudirsen and z-basivarsen

G&A EXPENSES - Increase in G&A expenses was primarily due to higher costs in preparation for the potential launch of z-rostudirsen

Company press release: ID:nGNX6cZhdV

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 EPS
Beat
-$0.73
-$0.77 (13 Analysts)
Q1 Net Income
Slight Miss*
-$120.85 mln
-$120.53 mln (11 Analysts)
Q1 Operating Income
Slight Miss*
-$125.28 mln
-$124.09 mln (11 Analysts)
Q1 Basic EPS
-$0.73
Q1 Operating Expenses
$125.28 mln


*Applies to a deviation of less than 1%; not applicable for per-share numbers.

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)